Looked at the S-3, here’s some thoughts: A Ja
Post# of 153887
(Total Views: 806)
Posted On: 08/20/2021 12:31:41 AM
Looked at the S-3, here’s some thoughts:
A Jan filing showed Fife on 1/14/21 as having 5.1mm shares. Add the 7.5mm he got (per 6/4 press release) equals 12.6mm. Today’s filing shows 7.75mm between his two entities Uptown and Streeterville. That implies he sold ~5mm shares between 1/14 and 8/18. He is getting another 5.7mm today.
So unless I’m missing something (very possible), Fife has absolutely been a seller. Of course it’s over 6 months but he’s been around…
Short interest has been largely unchanged over that timeframe. CYDY is not on the Reg SHO list. While conspiracy theories abound (naked shorts, offshore big pharma funded short sellers, 13D playing around), there are reasonable alternatives.
It could be as simple as some technical selling (Fife, Paulson, lack of momentum, shares out increased from 598 to 634 in 8 months) and fundamentals (no revs, trial uncertainty, noisy headlines) to explain the share price.
Both make me feel more comfortable with my investment because they can be understood and rectified. It’s a simple checklist of items that, if resolved favorably, which imo they will be, will make these prices look utterly ridiculous.
By end of year (or worst case early 22), revenues via EUA/Approval (anywhere) or a partnership (which can come at anytime) can violently change the course of the share price, the company, and medicine as we know it. Uplisting followed by a nice big block sale from Fife to “smart money / strong hands” funds and it’ll be like the flip of a lucrative light switch. That is, if you have skin in the game.
Rarely in life will great reward come without a fight and gut wrenching efforts (mental or physical). True in markets as well. Don’t blink. HODL.
A Jan filing showed Fife on 1/14/21 as having 5.1mm shares. Add the 7.5mm he got (per 6/4 press release) equals 12.6mm. Today’s filing shows 7.75mm between his two entities Uptown and Streeterville. That implies he sold ~5mm shares between 1/14 and 8/18. He is getting another 5.7mm today.
So unless I’m missing something (very possible), Fife has absolutely been a seller. Of course it’s over 6 months but he’s been around…
Short interest has been largely unchanged over that timeframe. CYDY is not on the Reg SHO list. While conspiracy theories abound (naked shorts, offshore big pharma funded short sellers, 13D playing around), there are reasonable alternatives.
It could be as simple as some technical selling (Fife, Paulson, lack of momentum, shares out increased from 598 to 634 in 8 months) and fundamentals (no revs, trial uncertainty, noisy headlines) to explain the share price.
Both make me feel more comfortable with my investment because they can be understood and rectified. It’s a simple checklist of items that, if resolved favorably, which imo they will be, will make these prices look utterly ridiculous.
By end of year (or worst case early 22), revenues via EUA/Approval (anywhere) or a partnership (which can come at anytime) can violently change the course of the share price, the company, and medicine as we know it. Uplisting followed by a nice big block sale from Fife to “smart money / strong hands” funds and it’ll be like the flip of a lucrative light switch. That is, if you have skin in the game.
Rarely in life will great reward come without a fight and gut wrenching efforts (mental or physical). True in markets as well. Don’t blink. HODL.
(19)
(0)